Research Advancements for HIV-associated Diffuse Large B-cell Lymphoma

This event will not be live streamed. You can submit your questions in advance by clicking the button "Notify when available"

Join us for an exciting episode as we dive into the latest advancements in treating HIV-associated diffuse large B-cell lymphoma (DLBCL). Doctor and researcher Kathryn Lurain joins HealthTree to talk about the latest research on treatment options, challenges and breakthroughs in patient care, and the future direction in HIV-associated DLBCL treatment.

Whether you’re a healthcare professional, a patient, or someone interested in the field, this podcast offers vital information and a deeper understanding of the innovative treatments for HIV-associated lymphoma.

Thank you to our episode sponsors, Regeneron, and Bristol Myers Squibb.

Dr. Kathryn Lurain shares about the advancements in HIV-associated DLBCL treatment, covering research, challenges, and future directions. 

She highlights the stigma and misconceptions in healthcare that contribute to the exclusion of HIV-positive individuals from trials, despite the ability to manage HIV as a chronic condition. Dr. Lurain emphasizes the need for inclusive clinical trials and suggests exploring specific therapies that target the unique aspects of HIV-related lymphomas, such as immunosuppression and viral infections like EBV and KSHV.

Additionally, Dr. Lurain describes a study she is working on that combines pomalidomide, an oral drug used in multiple myeloma, with the EPOCH chemotherapy regimen for treating HIV-associated lymphomas. The study aims to exploit pomalidomide’s ability to target cancer cells directly and mitigate the negative effects of viruses associated with lymphoma development in HIV-positive patients. She emphasizes the importance of including HIV-positive individuals in future trials to improve their treatment outcomes.